Pancreatic Cancer Research

ResearcherThomas Jefferson UniversityActive in the last 2 years

Grace A. McCarthy

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-6628-2755; OpenAlex author ID A5090284657. Sources: OpenAlex.

Their work

Papers
9 (first author 2, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
41
Papers, trials and grants by year

2019: 1 paper · 2020: 1 paper · 2021: 1 paper · 2022: 1 paper · 2023: 1 paper · 2024: 1 paper · 2025: 1 paper · 2026: 2 papers

Papers 9

  1. Impaired Adipose Anabolism in Pancreatic Cancer Cachexia Is Reversed by HuR Inhibition. Co-author DOI 10.1002/jcsm.70253↗
  2. The Posttranscriptional Regulator HuR Promotes Immune Evasion in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1136/jitc-2025-sitc2025.1250↗
  3. Post-transcriptional regulator HuR promotes immune evasion in pancreatic ductal adenocarcinoma Co-author DOI 10.1101/2025.02.07.632847↗
  4. The polymeric fluoropyrimidine CF10 overcomes limitations of 5-FU in pancreatic ductal adenocarcinoma cells through increased replication stress. Co-author DOI 10.1080/15384047.2024.2421584↗
  5. Deletion of the mRNA stability factor ELAVL1 (HuR) in pancreatic cancer cells disrupts the tumor microenvironment integrity. Co-author DOI 10.1093/narcan/zcad016↗
  6. The RNA-Binding Protein HuR Posttranscriptionally Regulates the Protumorigenic Activator YAP1 in Pancreatic Ductal Adenocarcinoma. First author DOI 10.1128/mcb.00018-22↗
  7. The FDA-Approved Anthelmintic Pyrvinium Pamoate Inhibits Pancreatic Cancer Cells in Nutrient-Depleted Conditions by Targeting the Mitochondria. First author DOI 10.1158/1535-7163.mct-20-0652↗
  8. Effect of Hypercapnia, an Element of Obstructive Respiratory Disorder, on Pancreatic Cancer Chemoresistance and Progression. Co-author DOI 10.1016/j.jamcollsurg.2019.12.033↗
  9. Poly (ADP) Ribose Glycohydrolase Can Be Effectively Targeted in Pancreatic Cancer. Co-author DOI 10.1158/0008-5472.can-18-3645↗

Closest collaborators

The 25 strongest of 41 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Jonathan Robert Brody · 9 shared papers, 2019–2026 · strength 1.45
  2. Rosalie C. Sears · 5 shared papers, 2022–2026 · strength 0.91
  3. Jennifer M. Finan · 4 shared papers, 2023–2026 · strength 0.78
  4. Aaron J. Grossberg · 3 shared papers, 2025–2026 · strength 0.70
  5. Yifei Guo · 3 shared papers, 2023–2026 · strength 0.59
  6. Katherine R. Pelz · 2 shared papers, 2026 · strength 0.50
  7. Aditi Jain · 4 shared papers, 2019–2023 · strength 0.45
  8. Lisa M. Coussens · 2 shared papers, 2025–2026 · strength 0.43
  9. Kevin Hawthorne · 2 shared papers, 2025–2026 · strength 0.43
  10. Katie E. Blise · 2 shared papers, 2025–2026 · strength 0.43
  11. Robert L Eil · 2 shared papers, 2025–2026 · strength 0.43
  12. Zheng Xia · 2 shared papers, 2025–2026 · strength 0.43
  13. Canping Chen · 2 shared papers, 2025–2026 · strength 0.43
  14. Christopher William Schultz · 4 shared papers, 2019–2022 · strength 0.39
  15. Charles J. Yeo · 4 shared papers, 2019–2022 · strength 0.39
  16. Avinoam Nevler · 4 shared papers, 2019–2022 · strength 0.39
  17. Samantha Z. Brown · 3 shared papers, 2020–2022 · strength 0.32
  18. Parham Diba · 1 shared paper, 2026 · strength 0.28
  19. Paige C. Arneson‐Wissink · 1 shared paper, 2026 · strength 0.28
  20. Vidhi M. Shah · 1 shared paper, 2026 · strength 0.22
  21. Matthew McCoy · 2 shared papers, 2021–2022 · strength 0.22
  22. Dan A. Dixon · 2 shared papers, 2021–2022 · strength 0.22
  23. Gordon Brent Mills · 1 shared paper, 2024 · strength 0.19
  24. Alex O. Haber · 1 shared paper, 2024 · strength 0.19
  25. Alexander Savio Ramos Guimaraes · 1 shared paper, 2023 · strength 0.17

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.